PUBLISHER: The Business Research Company | PRODUCT CODE: 1830851
PUBLISHER: The Business Research Company | PRODUCT CODE: 1830851
Oncology Clinical Trials Global Market Report 2025
Oncology clinical trials are research studies that assess new treatments, drugs, or approaches for preventing, detecting, or managing cancer in humans. These trials are designed to evaluate the safety, efficacy, and potential side effects of interventions before they become widely available. Oncology clinical trials play a crucial role in improving clinical outcomes and advancing cancer care.
The primary phases of oncology clinical trials include phase I, phase II, phase III, and phase IV. Phase I trials are early-stage studies focused on evaluating the safety, tolerability, and optimal dosage of a new cancer treatment, while also examining how the drug is absorbed, distributed, metabolized, and excreted in the body. Their study designs include interventional, observational, and expanded access trials, and therapeutic modalities encompass immunotherapy, targeted therapy, chemotherapy, cell and gene therapy, and others. These trials address indications such as lung cancer, breast cancer, colorectal cancer, prostate cancer, blood cancers, and more, with sponsors including pharmaceutical and biotech companies, academic and research institutions, government organizations, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The oncology clinical trials market research report is one of a series of new reports from The Business Research Company that provides oncology clinical trials market statistics, including oncology clinical trials industry global market size, regional shares, competitors with an oncology clinical trials market share, detailed oncology clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the oncology clinical trials industry. This oncology clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The oncology clinical trials market size has grown strongly in recent years. It will grow from $14.04 billion in 2024 to $14.99 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historic period can be attributed to the rising prevalence of cancer cases, increasing adoption of targeted cancer therapies, growing awareness of early cancer detection and screening, the expanding number of oncology-focused clinical research organizations, and higher patient participation facilitated by advocacy groups.
The oncology clinical trials market size is expected to see strong growth in the next few years. It will grow to $19.22 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth during the forecast period can be attributed to the rising demand for personalized and precision oncology treatments, increased focus on rare and orphan oncology indications, growing adoption of decentralized and virtual oncology trials, and expanding use of genomic sequencing for patient selection. Key trends expected during the forecast period include advancements in biomarker-based trials, the application of advanced data analytics in trial design, innovations in immuno-oncology therapies, integration of artificial intelligence and machine learning, development of patient-centric trial models, and incorporation of real-world data in trial evaluation.
The rising incidence of cancer is expected to drive the growth of the oncology clinical trials market in the coming years. Cancer incidence refers to the number of new cancer cases within a specific population over a defined period. This increase is largely attributed to unhealthy lifestyle habits, including poor diet, lack of physical activity, tobacco use, and excessive alcohol consumption, which elevate the risk of developing various types of cancer. Oncology clinical trials play a critical role in advancing cancer treatment by evaluating new therapies and interventions, improving patient outcomes through evidence-based research. They accelerate medical innovation by assessing the safety and efficacy of treatments, supporting progress in cancer prevention, diagnosis, and care. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that cancer cases diagnosed in Australia reached 160,570 in 2022, up by 3,789 cases from 156,781 in 2021. Consequently, the rising cancer incidence is fueling the growth of the oncology clinical trials market.
Key players in the oncology clinical trials market are focusing on technologically advanced solutions, such as AI-driven bioinformatics platforms, to enhance data analysis, speed patient recruitment, and optimize trial outcomes. Advanced bioinformatics platforms are sophisticated software systems that use computational tools and algorithms to collect, analyze, and interpret complex biological and clinical data for research and healthcare purposes. For instance, in September 2023, Deep 6 AI, a US-based healthcare technology company, launched an AI-powered genomics module designed to accelerate enrollment in precision medicine and oncology clinical trials. This module utilizes artificial intelligence and natural language processing to extract both structured and unstructured genomics data from electronic medical records, enabling real-time patient identification and accurate matching based on specific genetic markers. It allows researchers to search millions of records for over 19,000 genes and 30,000 mutation names, significantly speeding up patient recruitment and improving clinical trial efficiency.
In September 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, acquired Surface Oncology Inc. for \$66.9 million. This acquisition aims to strengthen Coherus's immuno-oncology pipeline, expand therapies targeting the tumor microenvironment, and enhance the clinical potential of its PD-1 inhibitor, toripalimab. Surface Oncology Inc. is a US-based clinical-stage immuno-oncology company conducting trials for novel cancer therapies.
Major players in the oncology clinical trials market are Pfizer Inc., Johnson & Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Genentech Inc., BeiGene Ltd., Seagen Inc.
North America was the largest region in the oncology clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oncology clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the oncology clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The oncology clinical trials market includes revenues earned by entities through designing and conducting cancer-related clinical research studies, providing patient recruitment and enrollment services, supplying oncology-specific laboratory testing and diagnostics, and managing data collection, monitoring, and regulatory compliance. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Oncology Clinical Trials Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on oncology clinical trials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for oncology clinical trials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oncology clinical trials market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Phase: Phase I; Phase II; Phase III; Phase IV
- 2) By Study Design: Interventional; Observational; Expanded Access
- 3) By Therapeutic Modality: Immunotherapy; Targeted Therapy; Chemotherapy; Cell And Gene Therapy; Other Therapeutic Modalities
- 4) By Indication: Lung Cancer; Breast Cancer; Colorectal Cancer; Prostate Cancer; Blood Cancer; Other Indications
- 5) By Sponsor Type: Pharmaceutical And Biotech Companies; Academic And Research Institutes; Government Organizations; Other Sponsor Types
- Subsegments:
- 1) By Phase I: Safety And Dosage Studies; Pharmacokinetics And Pharmacodynamics Studies; Biomarker Identification Studies
- 2) By Phase II: Efficacy And Side Effects Studies; Dose-Response Relationship Studies; Therapeutic Effectiveness Studies
- 3) By Phase III: Large-Scale Efficacy Studies; Comparative Effectiveness Studies; Multicenter Randomized Controlled Trials
- 4) By Phase IV: Post Marketing Surveillance Studies; Long-Term Safety Studies; Quality Of Life Studies
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck And Co. Inc.; AbbVie Inc.; Bayer AG; Novartis International AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; GSK plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Gilead Sciences Inc.; Amgen Inc.; Boehringer Ingelheim GmbH; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Genentech Inc.; BeiGene Ltd.; Seagen Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Oncology Clinical Trials Market Characteristics
3. Oncology Clinical Trials Market Trends And Strategies
4. Oncology Clinical Trials Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Oncology Clinical Trials Growth Analysis And Strategic Analysis Framework
- 5.1. Global Oncology Clinical Trials PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Oncology Clinical Trials Market Growth Rate Analysis
- 5.4. Global Oncology Clinical Trials Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Oncology Clinical Trials Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Oncology Clinical Trials Total Addressable Market (TAM)
6. Oncology Clinical Trials Market Segmentation
- 6.1. Global Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Phase I
- Phase II
- Phase III
- Phase IV
- 6.2. Global Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Interventional
- Observational
- Expanded Access
- 6.3. Global Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Cell And Gene Therapy
- Other Therapeutic Modalities
- 6.4. Global Oncology Clinical Trials Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Blood Cancer
- Other Indications
- 6.5. Global Oncology Clinical Trials Market, Segmentation By Sponsor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pharmaceutical And Biotech Companies
- Academic And Research Institutes
- Government Organizations
- Other Sponsor Types
- 6.6. Global Oncology Clinical Trials Market, Sub-Segmentation Of Phase I, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Safety And Dosage Studies
- Pharmacokinetics And Pharmacodynamics Studies
- Biomarker Identification Studies
- 6.7. Global Oncology Clinical Trials Market, Sub-Segmentation Of Phase II, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Efficacy And Side Effects Studies
- Dose-Response Relationship Studies
- Therapeutic Effectiveness Studies
- 6.8. Global Oncology Clinical Trials Market, Sub-Segmentation Of Phase III, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Large-Scale Efficacy Studies
- Comparative Effectiveness Studies
- Multicenter Randomized Controlled Trials
- 6.9. Global Oncology Clinical Trials Market, Sub-Segmentation Of Phase IV, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Post Marketing Surveillance Studies
- Long-Term Safety Studies
- Quality Of Life Studies
7. Oncology Clinical Trials Market Regional And Country Analysis
- 7.1. Global Oncology Clinical Trials Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Oncology Clinical Trials Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Oncology Clinical Trials Market
- 8.1. Asia-Pacific Oncology Clinical Trials Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Oncology Clinical Trials Market
- 9.1. China Oncology Clinical Trials Market Overview
- 9.2. China Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Oncology Clinical Trials Market
- 10.1. India Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Oncology Clinical Trials Market
- 11.1. Japan Oncology Clinical Trials Market Overview
- 11.2. Japan Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Oncology Clinical Trials Market
- 12.1. Australia Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Oncology Clinical Trials Market
- 13.1. Indonesia Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Oncology Clinical Trials Market
- 14.1. South Korea Oncology Clinical Trials Market Overview
- 14.2. South Korea Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Oncology Clinical Trials Market
- 15.1. Western Europe Oncology Clinical Trials Market Overview
- 15.2. Western Europe Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Oncology Clinical Trials Market
- 16.1. UK Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Oncology Clinical Trials Market
- 17.1. Germany Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Oncology Clinical Trials Market
- 18.1. France Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Oncology Clinical Trials Market
- 19.1. Italy Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Oncology Clinical Trials Market
- 20.1. Spain Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Oncology Clinical Trials Market
- 21.1. Eastern Europe Oncology Clinical Trials Market Overview
- 21.2. Eastern Europe Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Oncology Clinical Trials Market
- 22.1. Russia Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Oncology Clinical Trials Market
- 23.1. North America Oncology Clinical Trials Market Overview
- 23.2. North America Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Oncology Clinical Trials Market
- 24.1. USA Oncology Clinical Trials Market Overview
- 24.2. USA Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Oncology Clinical Trials Market
- 25.1. Canada Oncology Clinical Trials Market Overview
- 25.2. Canada Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Oncology Clinical Trials Market
- 26.1. South America Oncology Clinical Trials Market Overview
- 26.2. South America Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Oncology Clinical Trials Market
- 27.1. Brazil Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Oncology Clinical Trials Market
- 28.1. Middle East Oncology Clinical Trials Market Overview
- 28.2. Middle East Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Oncology Clinical Trials Market
- 29.1. Africa Oncology Clinical Trials Market Overview
- 29.2. Africa Oncology Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Oncology Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Oncology Clinical Trials Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Oncology Clinical Trials Market Competitive Landscape And Company Profiles
- 30.1. Oncology Clinical Trials Market Competitive Landscape
- 30.2. Oncology Clinical Trials Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
31. Oncology Clinical Trials Market Other Major And Innovative Companies
- 31.1. Novartis International AG
- 31.2. Sanofi S.A.
- 31.3. Bristol-Myers Squibb Company
- 31.4. AstraZeneca plc
- 31.5. GSK plc
- 31.6. Takeda Pharmaceutical Company Limited
- 31.7. Eli Lilly and Company
- 31.8. Gilead Sciences Inc.
- 31.9. Amgen Inc.
- 31.10. Boehringer Ingelheim GmbH
- 31.11. Teva Pharmaceutical Industries Ltd.
- 31.12. Regeneron Pharmaceuticals Inc.
- 31.13. Genentech Inc.
- 31.14. BeiGene Ltd.
- 31.15. Seagen Inc.
32. Global Oncology Clinical Trials Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Oncology Clinical Trials Market
34. Recent Developments In The Oncology Clinical Trials Market
35. Oncology Clinical Trials Market High Potential Countries, Segments and Strategies
- 35.1 Oncology Clinical Trials Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Oncology Clinical Trials Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Oncology Clinical Trials Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
